Purple Biotech shares are trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.
benzinga_article
Purple Biotech shares are trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.
